Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016289 · ClinicalTrials.gov registry record · Phase 2
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase 2 study of Primary Peritoneal Cavity Cancer and Recurrent Ovarian Epithelial Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00016289 is a Phase 2 study of Primary Peritoneal Cavity Cancer and Recurrent Ovarian Epithelial Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants, below the 102-participant average among 15 other Primary Peritoneal Cavity Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00016289, a Phase 2 study of Primary Peritoneal Cavity Cancer and Recurrent Ovarian Epithelial Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial to study the effectiveness of intraperitoneal interleukin-12 in treating patients who have ovarian epithelial cancer or primary peritoneal cancer. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cells. Giving interleukin-12 directly into the peritoneal cavity may kill cancer cells
Conditions Studied
Interventions
- BIOLOGICAL recombinant interleukin-12
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016289
The ClinicalTrials.gov registry entry for NCT00016289 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 15 other Primary Peritoneal Cavity Cancer trials with a reported enrollment target (71% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Peritoneal Cavity Cancer appearing as the primary indexed condition, and to 1 intervention - of which recombinant interleukin-12 is the first listed.
NCT00016289 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00016289 about?
NCT00016289 is a clinical study titled "Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Phase II trial to study the effectiveness of intraperitoneal interleukin-12 in treating patients who have ovarian epithelial cancer or primary peritoneal cancer. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cell...
What is the current status of trial NCT00016289?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2001-07.
What conditions does trial NCT00016289 study?
This clinical trial studies the following conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer.
What interventions are being tested in trial NCT00016289?
The interventions under investigation include: recombinant interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00016289?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00016289 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Peritoneal Cavity Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
RECRUITING · Phase 2
-
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
COMPLETED · Phase 2
-
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
COMPLETED · Phase 2
-
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
COMPLETED · Phase 2
-
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
COMPLETED · Phase 2
-
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Primary Peritoneal Cavity Cancer
All registered trials for this condition
Recurrent Ovarian Epithelial Cancer
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.